<p>劍橋投資研究顧問公司在最近向美國證券交易委員會提交的 13F 表格中表示，在第四季度將其在雅培（NYSE:ABT - 免費報告）的持股增加了 13.6%。該公司在本季度購買了 39,573 股後，持有該醫療產品製造商的 331,204 股股票。根據其最近向美國證券交易委員會的提交，劍橋投資研究顧問公司在雅培的持股價值為 41,497,000 美元。</p>
<p>獲取 <strong>雅培</strong> 的提醒：</p>
<ul>
<li>艾伯維發出健康趨勢跟隨信號：反彈即將到來？</li>
</ul>
<p>其他機構投資者最近也買入和賣出了該公司的股票。WealthPlan Investment Management LLC 在第四季度將其在雅培的持股增加了 258.7%。WealthPlan Investment Management LLC 現在擁有 23,713 股該醫療產品製造商的股票，價值為 2,971,000 美元，此前在上個季度又購買了 17,102 股。Noesis Capital Management Corp 在第四季度將其在雅培的持股增加了 9.9%。Noesis Capital Management Corp 現在擁有 1,966 股該醫療產品製造商的股票，價值為 246,000 美元，此前在此期間又購買了 177 股。Lawood &amp; Co.在第四季度購買了雅培的新頭寸，價值為 332,000 美元。Novare Capital Management LLC 在第四季度將其在雅培的持股增加了 1.3%。Novare Capital Management LLC 現在擁有 104,349 股該醫療產品製造商的股票，價值為 13,074,000 美元，此前在此期間又購買了 1,294 股。最後，Cauble &amp; Harre Wealth Management Inc.在第四季度購買了雅培的新頭寸，價值為 404,000 美元。目前 75.18% 的股票由機構投資者和對沖基金持有。</p>
<h2>內部買賣</h2>
<p>在其他消息中，董事 Daniel J. Starks 在 4 月 27 日星期一購買了 10,000 股公司的股票。每股購買價格為 92.65 美元，總價值為 926,500.00 美元。交易完成後，該董事直接持有公司 6,751,103 股股票，價值為 625,489,692.95 美元。這筆交易代表其持股增加了 0.15%。該購買在向證券交易委員會的提交中披露，可以通過此鏈接訪問。此外，高級副總裁 Eric Shroff 在 3 月 2 日星期一出售了 709 股雅培的股票。每股出售價格為 115.58 美元，總交易額為 81,946.22 美元。交易完成後，該高級副總裁直接持有公司 39,164 股股票，價值約為 4,526,575.12 美元。這代表其持股減少了 1.78%。該出售的披露在 SEC 提交中可用。在過去 90 天內，內部人士已出售 3,055 股公司股票，價值為 353,097 美元。0.46% 的股票由公司內部人士持有。</p>
<h2>華爾街分析師預測增長</h2>
<ul>
<li>雅培股票崩盤：反彈可能即將到來</li>
</ul>
<p>一些研究分析師對該股票發表了評論。Oppenheimer 在 4 月 17 日的研究報告中將雅培的目標價從 132.00 美元下調至 115.00 美元，並對該股票給予 “跑贏大盤” 的評級。Sanford C. Bernstein 在 4 月 17 日的研究報告中將雅培的目標價從 125.00 美元下調至 110.00 美元，並對該公司給予 “跑贏大盤” 的評級。巴克萊在 4 月 20 日的研究報告中將雅培的目標價從 144.00 美元下調至 143.00 美元，並對該公司給予 “增持” 的評級。美國銀行在 4 月 17 日的報告中將雅培的目標價從 150.00 美元下調至 120.00 美元，並對該公司給予 “買入” 的評級。最後，Leerink Partners 在 4 月 21 日的報告中將雅培的目標價從 119.00 美元下調至 106.00 美元，並對該公司給予 “市場表現” 的評級。兩位研究分析師對該股票給予強烈買入評級，十九位給予買入評級，五位給予持有評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “適度買入”，平均目標價為 119.43 美元。</p>
<p><strong>獲取我們最新的 ABT 研究報告</strong></p>
<h2>雅培股票表現</h2>
<ul>
<li>一家股息之王正在打折出售：雅培實驗室是醫療保健的便宜貨嗎？</li>
</ul>
<p>雅培的股票在週一開盤價為 84.49 美元。雅培的年低為 81.97 美元，年高為 139.06 美元。該公司的 50 日移動平均線為 99.02 美元，200 日移動平均線為 113.25 美元。該股票的市值為 1471.6 億美元，市盈率為 23.67，PEG 比率為 1.41，貝塔值為 0.65。該公司的債務與股本比率為 0.56，流動比率為 1.39，速動比率為 1.01。</p>
<p>雅培（NYSE:ABT - 獲取免費報告）最近在 4 月 16 日星期四發佈了季度財報。該醫療產品製造商報告本季度每股收益（EPS）為 1.15 美元，超出分析師一致預期的 1.14 美元，超出 0.01 美元。該業務在本季度的收入為 111.6 億美元，而分析師預期為 109.9 億美元。雅培的淨利潤率為 13.90%，股本回報率為 17.62%。該公司的收入較去年同期增長了 7.8%。在去年同期，該公司每股收益為 1.09 美元。雅培已將其 2026 財年的指引設定為每股收益 5.380-5.580 美元，2026 年第二季度的指引設定為每股收益 1.250-1.310 美元。平均而言，股票研究分析師預計雅培在當前年度的每股收益將達到 5.48 美元。</p>
<h2>雅培宣佈分紅</h2>
<p>該公司最近宣佈了季度股息，並於 5 月 15 日（星期五）支付。4 月 15 日（星期三）登記在冊的股東獲得了每股 0.63 美元的股息。該股息的除息日為 4 月 15 日（星期三）。這相當於每年 2.52 美元的股息，股息收益率為 3.0%。雅培的股息支付比率（DPR）目前為 70.59%。</p>
<h2>關於雅培</h2>
<p>（免費報告）</p>
<p>雅培是一家全球醫療保健公司，總部位於伊利諾伊州的雅培公園，開發、生產和銷售廣泛的醫療產品和服務。雅培成立於 1888 年，通過多個業務領域運營，專注於診斷、醫療設備、營養品和成熟藥品。該公司向醫院、診所、實驗室、零售商和直接面向消費者的渠道提供旨在診斷、治療和管理各種健康狀況的產品。</p>
<p>在診斷領域，雅培提供實驗室和現場檢測平台及試劑，用於檢測傳染病、慢性疾病和生物標誌物；其 Alinity 系列儀器和快速檢測解決方案就是這一能力的例子。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票超過雅培</li>
<li>Robinhood、SoFi 和 Webull 講述了截然不同的故事</li>
<li>當博通市值超過 2 萬億美元時，私人信貸巨頭想要參與</li>
<li>通過這些 ETF 瞄準火熱的分拆和合並領域</li>
<li>隨着人工智能內存需求激增，三星加入 1 萬億美元俱樂部</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在雅培嗎？</h2>
<p>在考慮雅培之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而雅培不在名單上。</p>
<p>雖然雅培目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

雅培

美國制藥 ETF - iShares

美國醫藥設備 ETF - iShares

標普健康醫療設備 ETF - SPDR

基因改革 ETF - ARK

醫療業 ETF - Vanguard

標普全球醫療股指數 ETF - iShares

醫療業 ETF - SPDR

<p>劍橋投資研究顧問公司（Cambridge Investment Research Advisors Inc.）在第四季度將其在雅培（Abbott Laboratories，NYSE:ABT）的持股增加了 13.6%，目前持有 331,204 股，價值 4150 萬美元。其他投資者也提高了他們的持股比例。內部交易方面，董事丹尼爾·J·斯塔克斯（Daniel J. Starks）購買了 10,000 股，高級副總裁埃裏克·肖夫（Eric Shroff）出售了 709 股。分析師已調整了雅培的目標價格，平均目標為 119.43 美元，並給予 “適度買入” 的評級</p>

<p>Cambridge Investment Research Advisors Inc. raised its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 13.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 331,204 shares of the healthcare product maker's stock after purchasing an additional 39,573 shares during the quarter. Cambridge Investment Research Advisors Inc.'s holdings in Abbott Laboratories were worth $41,497,000 as of its most recent filing with the SEC.</p>
<div class="lb-trans"><p>劍橋投資研究顧問公司在最近向美國證券交易委員會提交的 13F 表格中表示，在第四季度將其在雅培（NYSE:ABT - 免費報告）的持股增加了 13.6%。該公司在本季度購買了 39,573 股後，持有該醫療產品製造商的 331,204 股股票。根據其最近向美國證券交易委員會的提交，劍橋投資研究顧問公司在雅培的持股價值為 41,497,000 美元。</p>
</div><p>Get <strong>Abbott Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>雅培</strong> 的提醒：</p>
</div><ul>
<li>AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?</li>
</ul>
<div class="lb-trans"><ul>
<li>艾伯維發出健康趨勢跟隨信號：反彈即將到來？</li>
</ul>
</div><p>Other institutional investors also recently bought and sold shares of the company. WealthPlan Investment Management LLC raised its position in shares of Abbott Laboratories by 258.7% in the fourth quarter. WealthPlan Investment Management LLC now owns 23,713 shares of the healthcare product maker's stock valued at $2,971,000 after buying an additional 17,102 shares during the last quarter. Noesis Capital Mangement Corp boosted its stake in shares of Abbott Laboratories by 9.9% in the fourth quarter. Noesis Capital Mangement Corp now owns 1,966 shares of the healthcare product maker's stock valued at $246,000 after purchasing an additional 177 shares during the period. Lawood &amp; Co. purchased a new position in shares of Abbott Laboratories in the fourth quarter valued at $332,000. Novare Capital Management LLC boosted its stake in shares of Abbott Laboratories by 1.3% in the fourth quarter. Novare Capital Management LLC now owns 104,349 shares of the healthcare product maker's stock valued at $13,074,000 after purchasing an additional 1,294 shares during the period. Finally, Cauble &amp; Harre Wealth Management Inc. bought a new position in Abbott Laboratories during the 4th quarter valued at $404,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他機構投資者最近也買入和賣出了該公司的股票。WealthPlan Investment Management LLC 在第四季度將其在雅培的持股增加了 258.7%。WealthPlan Investment Management LLC 現在擁有 23,713 股該醫療產品製造商的股票，價值為 2,971,000 美元，此前在上個季度又購買了 17,102 股。Noesis Capital Management Corp 在第四季度將其在雅培的持股增加了 9.9%。Noesis Capital Management Corp 現在擁有 1,966 股該醫療產品製造商的股票，價值為 246,000 美元，此前在此期間又購買了 177 股。Lawood &amp; Co.在第四季度購買了雅培的新頭寸，價值為 332,000 美元。Novare Capital Management LLC 在第四季度將其在雅培的持股增加了 1.3%。Novare Capital Management LLC 現在擁有 104,349 股該醫療產品製造商的股票，價值為 13,074,000 美元，此前在此期間又購買了 1,294 股。最後，Cauble &amp; Harre Wealth Management Inc.在第四季度購買了雅培的新頭寸，價值為 404,000 美元。目前 75.18% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣</h2>
</div><p>In other news, Director Daniel J. Starks purchased 10,000 shares of the company's stock in a transaction dated Monday, April 27th. The shares were bought at an average price of $92.65 per share, with a total value of $926,500.00. Following the completion of the transaction, the director directly owned 6,751,103 shares in the company, valued at $625,489,692.95. This trade represents a 0.15% increase in their position. The purchase was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Also, SVP Eric Shroff sold 709 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $81,946.22. Following the completion of the transaction, the senior vice president directly owned 39,164 shares in the company, valued at approximately $4,526,575.12. This represents a 1.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 3,055 shares of company stock valued at $353,097. 0.46% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他消息中，董事 Daniel J. Starks 在 4 月 27 日星期一購買了 10,000 股公司的股票。每股購買價格為 92.65 美元，總價值為 926,500.00 美元。交易完成後，該董事直接持有公司 6,751,103 股股票，價值為 625,489,692.95 美元。這筆交易代表其持股增加了 0.15%。該購買在向證券交易委員會的提交中披露，可以通過此鏈接訪問。此外，高級副總裁 Eric Shroff 在 3 月 2 日星期一出售了 709 股雅培的股票。每股出售價格為 115.58 美元，總交易額為 81,946.22 美元。交易完成後，該高級副總裁直接持有公司 39,164 股股票，價值約為 4,526,575.12 美元。這代表其持股減少了 1.78%。該出售的披露在 SEC 提交中可用。在過去 90 天內，內部人士已出售 3,055 股公司股票，價值為 353,097 美元。0.46% 的股票由公司內部人士持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><ul>
<li>Abbott Stock Crash: Rebound Could Be Coming Fast</li>
</ul>
<div class="lb-trans"><ul>
<li>雅培股票崩盤：反彈可能即將到來</li>
</ul>
</div><p>A number of research analysts have commented on the stock. Oppenheimer reduced their price objective on shares of Abbott Laboratories from $132.00 to $115.00 and set an &#34;outperform&#34; rating on the stock in a research note on Friday, April 17th. Sanford C. Bernstein decreased their target price on shares of Abbott Laboratories from $125.00 to $110.00 and set an &#34;outperform&#34; rating for the company in a research report on Friday, April 17th. Barclays reduced their price objective on shares of Abbott Laboratories from $144.00 to $143.00 and set an &#34;overweight&#34; rating for the company in a research report on Monday, April 20th. Bank of America decreased their target price on shares of Abbott Laboratories from $150.00 to $120.00 and set a &#34;buy&#34; rating for the company in a report on Friday, April 17th. Finally, Leerink Partners decreased their target price on shares of Abbott Laboratories from $119.00 to $106.00 and set a &#34;market perform&#34; rating for the company in a report on Tuesday, April 21st. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $119.43.</p>
<div class="lb-trans"><p>一些研究分析師對該股票發表了評論。Oppenheimer 在 4 月 17 日的研究報告中將雅培的目標價從 132.00 美元下調至 115.00 美元，並對該股票給予 “跑贏大盤” 的評級。Sanford C. Bernstein 在 4 月 17 日的研究報告中將雅培的目標價從 125.00 美元下調至 110.00 美元，並對該公司給予 “跑贏大盤” 的評級。巴克萊在 4 月 20 日的研究報告中將雅培的目標價從 144.00 美元下調至 143.00 美元，並對該公司給予 “增持” 的評級。美國銀行在 4 月 17 日的報告中將雅培的目標價從 150.00 美元下調至 120.00 美元，並對該公司給予 “買入” 的評級。最後，Leerink Partners 在 4 月 21 日的報告中將雅培的目標價從 119.00 美元下調至 106.00 美元，並對該公司給予 “市場表現” 的評級。兩位研究分析師對該股票給予強烈買入評級，十九位給予買入評級，五位給予持有評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “適度買入”，平均目標價為 119.43 美元。</p>
</div><p><strong>Get Our Latest Research Report on ABT</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 ABT 研究報告</strong></p>
</div><h2>Abbott Laboratories Stock Performance</h2>
<div class="lb-trans"><h2>雅培股票表現</h2>
</div><ul>
<li>A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?</li>
</ul>
<div class="lb-trans"><ul>
<li>一家股息之王正在打折出售：雅培實驗室是醫療保健的便宜貨嗎？</li>
</ul>
</div><p>Shares of ABT opened at $84.49 on Monday. Abbott Laboratories has a one year low of $81.97 and a one year high of $139.06. The company has a 50-day moving average of $99.02 and a two-hundred day moving average of $113.25. The stock has a market cap of $147.16 billion, a price-to-earnings ratio of 23.67, a PEG ratio of 1.41 and a beta of 0.65. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01.</p>
<div class="lb-trans"><p>雅培的股票在週一開盤價為 84.49 美元。雅培的年低為 81.97 美元，年高為 139.06 美元。該公司的 50 日移動平均線為 99.02 美元，200 日移動平均線為 113.25 美元。該股票的市值為 1471.6 億美元，市盈率為 23.67，PEG 比率為 1.41，貝塔值為 0.65。該公司的債務與股本比率為 0.56，流動比率為 1.39，速動比率為 1.01。</p>
</div><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.14 by $0.01. The business had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm's revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, equities research analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current year.</p>
<div class="lb-trans"><p>雅培（NYSE:ABT - 獲取免費報告）最近在 4 月 16 日星期四發佈了季度財報。該醫療產品製造商報告本季度每股收益（EPS）為 1.15 美元，超出分析師一致預期的 1.14 美元，超出 0.01 美元。該業務在本季度的收入為 111.6 億美元，而分析師預期為 109.9 億美元。雅培的淨利潤率為 13.90%，股本回報率為 17.62%。該公司的收入較去年同期增長了 7.8%。在去年同期，該公司每股收益為 1.09 美元。雅培已將其 2026 財年的指引設定為每股收益 5.380-5.580 美元，2026 年第二季度的指引設定為每股收益 1.250-1.310 美元。平均而言，股票研究分析師預計雅培在當前年度的每股收益將達到 5.48 美元。</p>
</div><h2>Abbott Laboratories Announces Dividend</h2>
<div class="lb-trans"><h2>雅培宣佈分紅</h2>
</div><p>The company also recently declared a quarterly dividend, which was paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th were given a $0.63 dividend. The ex-dividend date of this dividend was Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.0%. Abbott Laboratories's dividend payout ratio (DPR) is currently 70.59%.</p>
<div class="lb-trans"><p>該公司最近宣佈了季度股息，並於 5 月 15 日（星期五）支付。4 月 15 日（星期三）登記在冊的股東獲得了每股 0.63 美元的股息。該股息的除息日為 4 月 15 日（星期三）。這相當於每年 2.52 美元的股息，股息收益率為 3.0%。雅培的股息支付比率（DPR）目前為 70.59%。</p>
</div><h2>About Abbott Laboratories</h2>
<div class="lb-trans"><h2>關於雅培</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.</p>
<div class="lb-trans"><p>雅培是一家全球醫療保健公司，總部位於伊利諾伊州的雅培公園，開發、生產和銷售廣泛的醫療產品和服務。雅培成立於 1888 年，通過多個業務領域運營，專注於診斷、醫療設備、營養品和成熟藥品。該公司向醫院、診所、實驗室、零售商和直接面向消費者的渠道提供旨在診斷、治療和管理各種健康狀況的產品。</p>
</div><p>In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.</p>
<div class="lb-trans"><p>在診斷領域，雅培提供實驗室和現場檢測平台及試劑，用於檢測傳染病、慢性疾病和生物標誌物；其 Alinity 系列儀器和快速檢測解決方案就是這一能力的例子。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Abbott Laboratories</li>
<li>Robinhood, SoFi, and Webull Are Telling Very Different Stories</li>
<li>As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In</li>
<li>Target the Red-Hot Spin-Off and Merger Space With These ETFs</li>
<li>Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過雅培</li>
<li>Robinhood、SoFi 和 Webull 講述了截然不同的故事</li>
<li>當博通市值超過 2 萬億美元時，私人信貸巨頭想要參與</li>
<li>通過這些 ETF 瞄準火熱的分拆和合並領域</li>
<li>隨着人工智能內存需求激增，三星加入 1 萬億美元俱樂部</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在雅培嗎？</h2>
</div><p>Before you consider Abbott Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮雅培之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而雅培不在名單上。</p>
</div><p>While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然雅培目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Abbott Laboratories $ABT Shares Purchased by Cambridge Investment Research Advisors Inc.

Market Beat

艾伯維

奧本海默控股

巴克萊銀行

美國銀行

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

劍橋投資研究顧問公司購買了雅培公司 $ABT 的股票